November 2, 2021 01:00 PM EDTUpdated November 3, 04:59 PM

MarketingRx roundup: J&J boosts health equity goals in 6-city challenge; Allergan Aesthetics kicks off breast cancer efforts

Beth Snyder Bulik

Senior Editor

Johnson & Johnson is looking for big ideas from small entrepreneurs. Spurred by the pandemic health inequities and ongoing racial injustice in local communities, J …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

MarketingRx roundup: J&J boosts health equity goals in 6-city challenge; Allergan Aesthetics kicks off breast cancer efforts

Beth Snyder Bulik

Senior Editor

Sign up to read this article for free.

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

Mar­ket­ingRx roundup: J&J boosts health eq­ui­ty goals in 6-city chal­lenge; Al­ler­gan Aes­thet­ics kicks off breast can­cer ef­forts

Beth Snyder Bulik

Senior Editor

Sign up to read this article for free.

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

MarketingRx roundup: J&J boosts health equity goals in 6-city challenge; Allergan Aesthetics kicks off breast cancer efforts

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?